Risk of Colorectal Cancer and Dysplasia in Asian Ulcerative Colitis Patients

Systematic review with meta‐analysis: use of 5‐aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease

“…Twenty‐one studies contributed data specific for UC, while only five studies for CD . The reduction in CRN risk associated with 5‐ASA use was 50% among UC patients (RR = 0.50, 95% CI: 0.38–0.64), but weaker and nonsignificant among patients with CD (RR = 0.76, 95% CI: 0.43–1.33) (Table ).…”

“…Finally, we identified and included 31 independent studies, which met the predefined eligibility criteria; 28-58 three of them had been published solely as conference abstracts. [56][57][58] Five additional studies were excluded due to the rule for multiple publications involving the same population. [59][60][61][62][63] The full list of excluded studies, with reasons for exclusion, is given in the Appendix S1.…”

“…The full text was read and the reference lists were carefully investigated. Finally, we identified and included 31 independent studies, which met the predefined eligibility criteria; three of them had been published solely as conference abstracts . Five additional studies were excluded due to the rule for multiple publications involving the same population .…”

“…Thirty‐one studies selected for inclusion analysed exposure to 5‐ASA and risk of developing CRN, and reported (or provided sufficient data to determine) an effect estimate and a confidence interval. Among them, 10 were cohort studies, and the remaining 21 were case–control studies . Twelve were population‐based, while 19 were hospital‐based studies .…”

“…Among them, 10 were cohort studies, and the remaining 21 were case–control studies . Twelve were population‐based, while 19 were hospital‐based studies . Seventeen studies analysed patients with UC, two studies had patients with CD, and 12 studies included both UC and CD patients …”